<?xml version="1.0" encoding="UTF-8"?>
<p id="p0075">As examples of the most common treatment options, chloroquine and hydroxychloroquine, both antimalarial agents with anti-inflammatory and immunomodulatory activities, have shown inhibitory activity for SARS-CoV-2 similar to previous studies on SARS-CoV-1 and MERS-CoV (
 <xref rid="bib49" ref-type="bibr">Sanders et al., 2020</xref>). These two treatments are being investigated for use by patients with COVID-19 based on positive 
 <italic>in vitro</italic> and limited clinical data. In addition, azithromycin, a macrolide antibiotic, was found to raise the efficacy of hydroxychloroquine as a complementary therapy (
 <xref rid="bib13" ref-type="bibr">Gautret et al., 2020</xref>).
</p>
